AstraZeneca Plc has announced the allocation of an additional $100 million to its venture capital arm, MedImmune Ventures, increasing the total capital under management to $400 million. The fund invests in private life science companies. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
